SC
CHRS icon

Swan Capital’s Coherus Oncology CHRS Stock Holding History

Swan Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.2K Hold
1,300
– – ﹤0.01% 351
2025
Q4 		$1.85K Hold
1,300
– – ﹤0.01% 338
2025
Q3 		$2.13K Hold
1,300
– – ﹤0.01% 306
2025
Q2 		$951 Hold
1,300
– – ﹤0.01% 383
2025
Q1 		$1.05K Hold
1,300
– – ﹤0.01% 282
2024
Q4 		$1.79K Hold
1,300
– – ﹤0.01% 238
2024
Q3 		$1.35K Hold
1,300
– – ﹤0.01% 246
2024
Q2 		$2.25K Buy
+1,300
New +$2.62K ﹤0.01% 194

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Swan Capital's CHRS Position: Q1 2026 in Review

Swan Capital held its Coherus Oncology (CHRS) position steady in Q1 2026 at 1,300 shares worth $2.2K. The position accounts for ﹤0.01% of the portfolio, ranked #351.

Swan Capital first reported a position in CHRS in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.25K in Q2 2024. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Swan Capital held 1,300 shares of Coherus Oncology worth $2.2K as of Q1 2026.
  • Swan Capital left its Coherus Oncology share count unchanged in Q1 2026.
  • Coherus Oncology made up ﹤0.01% of Swan Capital's portfolio in Q1 2026, its #351 holding.
  • Swan Capital first reported a position in Coherus Oncology in Q2 2024 and has held it in 8 quarters since.
  • Swan Capital's Coherus Oncology position peaked at $2.25K in Q2 2024.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Swan Capital's 13F filing for Q1 2026, filed 14 May 2026.